A 26‐week feasibility study comparing the efficacy and safety of modified‐release prednisone with immediate‐release prednisolone in newly diagnosed cases of giant cell arteritis

Abstract

This trial shows that MR prednisone appears to be a safe and effective treatment for GCA with a similar outcome profile to standard IR prednisolone.